Back to search results

Observational Study for Pancreatic Cystic Lesions

This study is looking for people with pancreatic cystic lesions (PCLs), acute pancreatitis, chronic pancreatitis, pancreatic cancer, or congenital pancreatic issues. The goal is to find biological markers in your blood and cyst fluid that can help predict if a pancreatic cyst will develop into a tumor. You would have a pancreatic cyst aspiration, where a small amount of fluid is taken from the cyst. Researchers will then study this fluid and your blood for potential markers. The study aims to see if these markers can detect early tumor progression within two years. This is an observational study, meaning researchers will collect information without giving you a specific treatment.

Study design
This is a 10-year observational study involving 1000 participants. It is designed to collect and store pancreatic cyst fluid and blood samples.
What's involved
You would provide blood samples and a pancreatic cyst fluid sample through aspiration. Researchers will also collect information from your medical records.
Compensation
Not stated in the trial record.
Follow-up
The study will look for early progression to tumor, measured at 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02647177

A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst Lesions

Recruiting
Not specifiedAges 18+Observational
The University of Texas Health Science Center, Houston
~1,000 participants
Updated 2025-08-15 on ClinicalTrials.gov
What's tested:Pancreatic Cyst Aspiration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Detection of early progression to Tumor
Measured over 2 years

Conditions

Pancreatic Cystic Lesions

Explore related trials

Acute PancreatitisChronic PancreatitisCongenital developmental anomalies of the pancreasPancreatic CarcinomaPancreatic Cystic Lesion

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Nirav C Thosani, MD MHA · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center, Houston

Who to contact

Prithvi Patil, MS
[email protected]
(713) 500-6654
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of Pancreatic Cystic Lesions (PCLs) or Acute Pancreatitis (AP) or chronic pancreatitis(CP) or Pancreatic Cancer (PC) (any stage/grade) or congenital developmental anomalies of the pancreas.
Any combination of the diagnoses above.
Patients must provide written informed consent for the collection of blood specimens for research purposes.
Patients with PCLs must provide informed consent for collection of excess cyst fluid aspirate remaining after testing for routine standard of care
Patients with pancreatic Cystic Lesions (PCLs) or AP or CP or PC (any stage/grade) or congenital developmental anomalies of the pancreas undergoing surgery must provide informed consent for collection of surgical specimen

Exclusion

Patients with co-existing malignancies of other organs (or prior history of such)
Patients unable to provide informed consent
Patients unable to complete follow up

What this trial measures

  • Detection of early progression to Tumor2 years

    To identify any correlation between higher expression levels with early progression to malignant changes in the pancreas